Theranostic profiling for actionable aberrations in advanced high risk osteosarcoma with aggressive biology reveals high molecular diversity: the human fingerprint hypothesis

Abstract

The survival of patients with advanced osteosarcoma is poor with limited therapeutic options. There is an urgent need for new targeted therapies based on biomarkers. Recently, theranostic molecular profiling services for cancer patients by CLIA-certified commercial companies as well as in-house profiling in academic medical centers have expanded exponentially. We evaluated molecular profiles of patients with advanced osteosarcoma whose tumor tissue had been analyzed by one of the following methods: 1. 182-gene next-generation exome sequencing (Foundation Medicine, Boston, MA), 2. Immunohistochemistry (IHC)/PCR-based panel (CARIS Target Now, Irving, Tx), 3. Comparative genome hybridization (Oncopath, San Antonio, TX). 4. Single-gene PCR assays, PTEN IHC (MDACC CLIA), 5. UT Houston morphoproteomics (Houston, TX). The most common actionable aberrations occur in the PI3K/PTEN/ mTOR pathway. No patterns in genomic alterations beyond the above are readily identifiable, and suggest both high molecular diversity in osteosarcoma and the need for more analyses to define distinct subgroups of osteosarcoma defined by genomic alterations. Based on our preliminary observations we hypothesize that the biology of aggressive and the metastatic phenotype osteosarcoma at the molecular level is similar to human fingerprints, in that no two tumors are identical. Further large scale analyses of osteosarcoma samples are warranted to test this hypothesis.

RNA sequencing of Sleeping Beauty transposon-induced tumors detects transposon-RNA fusions in forward genetic cancer screens

“…Rats showed dose-dependent increases in osteosarcoma tumors following daily treatment with Pth (Vahle et al 2002), independently validating that Pth has a role in osteosarcoma development. PTPRD is a protein tyrosine phosphatase, and a frameshift mutation was described in a human osteosarcoma patient (Egas-Bejar et al 2014). Finally, a TGFBR1 variant was associated with osteosarcoma susceptibility in a Chinese population (Hu et al 2010).…”

Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors

“…Clinical research studies continue to demonstrate the impact of mutations in multiple pathways and show how those interact to cause sensitivity or resistance to both chemotherapeutic and targeted therapies 3, 24, 25 . The JAX-CTP™ is designed to identify mutations in 190 potentially actionable genes across multiple cancer relevant pathways (figure 4) to facilitate the selection of the appropriate therapeutic strategy.…”

Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma

“…The mTOR pathway is abnormally activated in sarcomas including, but not limited to, osteosarcoma. 95 In human cancers the activation of the mTOR signaling may occur by a variety of means. The receptors may be constitutively activated, as seen in osteosarcoma cell lines with poor prognosis, 96 or downstream effectors of mTOR may be altered in a way that leads to increased mTOR pathway activity.…”